Velocity’s research site in Albuquerque was founded in 2017 as the fourth site of MedPharmics and acquired by Velocity in 2022. Since its inception, the site has conducted trials in Infectious Diseases and Women’s Health, including over 15 vaccine trials. Our Albuquerque site played an integral role during the height of the COVID-19 pandemic, conducting COVID-19 trials for both children and adults.
The site is easily accessible. Additionally, half of the clinic staff is bilingual and can comfortably accommodate Spanish speaking patients. All trials conducted at the site are performed in accordance with ICH and FDA guidelines, and in compliance with GCP. The Albuquerque team is committed to being a resource for study volunteers, to providing the highest quality of patient care with compassion and kindness and to advancing medicine through research.